• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Globus Medical Inc.

    2/5/25 1:23:39 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care
    Get the next $GMED alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 13)


    GLOBUS MEDICAL INC

    (Name of Issuer)


    Class A Common Stock

    (Title of Class of Securities)


    379577208

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    379577208


    1Names of Reporting Persons

    BlackRock, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    10,284,375.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    10,636,609.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,636,609.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    GLOBUS MEDICAL INC
    (b)Address of issuer's principal executive offices:

    2560 GENERAL ARMISTEAD AVENUE AUDUBON PA 19403
    Item 2. 
    (a)Name of person filing:

    BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
    (b)Address or principal business office or, if none, residence:

    BlackRock, Inc. 50 Hudson Yards New York, NY 10001
    (c)Citizenship:

    See Item 4 of Cover Page
    (d)Title of class of securities:

    Class A Common Stock
    (e)CUSIP No.:

    379577208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    10636609
    (b)Percent of class:

    7.8  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    10284375

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    10636609

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of GLOBUS MEDICAL INC. No one person's interest in the common stock of GLOBUS MEDICAL INC is more than five percent of the total outstanding common shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit 99
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BlackRock, Inc.
     
    Signature:Spencer Fleming
    Name/Title:Managing Director
    Date:02/05/2025
    Get the next $GMED alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GMED

    DatePrice TargetRatingAnalyst
    1/30/2026$112.00Hold → Buy
    Needham
    1/27/2026$110.00Buy
    TD Cowen
    11/7/2025$93.00Hold → Buy
    Truist
    11/7/2025$91.00Neutral → Buy
    BofA Securities
    10/28/2025$64.00Hold
    Stifel
    5/27/2025Buy → Neutral
    BTIG Research
    1/10/2025$97.00Underperform → Neutral
    BofA Securities
    12/2/2024$83.00 → $100.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $GMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Norwalk Leslie V

    4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

    1/23/26 5:12:35 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by President, CEO Pfeil Keith W

    4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

    1/23/26 5:10:35 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Senior Vice President, CFO Kline Kyle

    4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

    1/23/26 5:05:39 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $GMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Globus Medical upgraded by Needham with a new price target

    Needham upgraded Globus Medical from Hold to Buy and set a new price target of $112.00

    1/30/26 6:55:35 AM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Globus Medical with a new price target

    TD Cowen initiated coverage of Globus Medical with a rating of Buy and set a new price target of $110.00

    1/27/26 8:46:26 AM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Globus Medical upgraded by Truist with a new price target

    Truist upgraded Globus Medical from Hold to Buy and set a new price target of $93.00

    11/7/25 8:06:34 AM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $GMED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

    AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-reported basis. Full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5 percent over the prior year on an as-reported basis. "We're thrilled with our preliminary Q4 results, capping off a strong finish to 2025," commented Keith Pfeil, President and Chief Executive Officer.

    1/7/26 4:27:58 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Globus Medical Reports Third Quarter 2025 Results

    AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0 millionGAAP diluted earnings per share ("EPS") was $0.88 and non-GAAP diluted EPS was $1.18, increasing 134.0% and 42.6%, respectively "We are pleased with the strength of our overall results and

    11/6/25 4:15:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Globus Medical Schedules Third Quarter Earnings Release and Conference Call

    AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2025 after the market close on Thursday, November 6, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events

    10/16/25 4:30:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $GMED
    SEC Filings

    View All

    Globus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GLOBUS MEDICAL INC (0001237831) (Filer)

    1/7/26 4:32:24 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Globus Medical Inc.

    144 - GLOBUS MEDICAL INC (0001237831) (Subject)

    11/12/25 8:45:11 AM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Globus Medical Inc.

    10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)

    11/6/25 5:10:54 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $GMED
    Financials

    Live finance-specific insights

    View All

    Globus Medical Reports Third Quarter 2025 Results

    AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0 millionGAAP diluted earnings per share ("EPS") was $0.88 and non-GAAP diluted EPS was $1.18, increasing 134.0% and 42.6%, respectively "We are pleased with the strength of our overall results and

    11/6/25 4:15:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Globus Medical Schedules Third Quarter Earnings Release and Conference Call

    AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2025 after the market close on Thursday, November 6, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events

    10/16/25 4:30:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Globus Medical Reports Second Quarter 2025 Results

    AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. Worldwide net sales were $745.3 million, an increase of 18.4%, or an increase of 17.6% on a constant currency basisGAAP net income for the quarter was $202.8 millionGAAP diluted earnings per share ("EPS") was $1.49 and non-GAAP diluted EPS was $0.86 "Q2 results were led by our US Spine business, growing 5.7%, as reported and 7.4% on a day-adjusted basis. US Spine had sustained momentum during the quarter, posting its highest sequential revenue growth since the second quarter of 2022,"

    8/7/25 4:15:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $GMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

    SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

    2/14/24 4:08:54 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

    SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

    2/13/24 5:06:16 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

    SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

    2/13/24 4:05:32 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $GMED
    Leadership Updates

    Live Leadership Updates

    View All

    Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

    CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

    2/6/25 8:30:00 AM ET
    $EXAS
    $GE
    $GMED
    Medical Specialities
    Health Care
    Consumer Electronics/Appliances
    Technology

    IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

    MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

    11/11/21 7:26:31 PM ET
    $BEAT
    $GMED
    $GTHX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Electronics

    Axonics® Announces Appointment of David M. Demski to Board of Directors

    IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a curren

    12/14/20 8:00:00 AM ET
    $AXNX
    $GMED
    Medical/Dental Instruments
    Health Care